Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-10-27
2011-11-22
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S009100, C530S350000, C514S002600
Reexamination Certificate
active
08062643
ABSTRACT:
The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5183462 (1993-02-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6506399 (2003-01-01), Donovan
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6667041 (2003-12-01), Schmidt
patent: 6939852 (2005-09-01), Graham
patent: 7001602 (2006-02-01), Schmidt
patent: 7153514 (2006-12-01), Schmidt
patent: 7429387 (2008-09-01), Schmidt
patent: 7449192 (2008-11-01), Schmidt
patent: 7455845 (2008-11-01), Schmidt
patent: 7470431 (2008-12-01), Schmidt
patent: 2004/0180065 (2004-09-01), Schmidt
patent: 2005/0048084 (2005-03-01), Schmidt
patent: 2005/0049175 (2005-03-01), Schmidt
patent: 2005/0112147 (2005-05-01), Schmidt
patent: 2005/0159337 (2005-07-01), Schmidt
patent: 2005/0175636 (2005-08-01), Donovan
patent: 2009/0004312 (2009-01-01), Schmidt
patent: 2009/0028974 (2009-01-01), Schmidt
patent: 2009/0068227 (2009-03-01), Schmidt
patent: 2005 234633 (2007-04-01), None
patent: 6-183975 (1994-07-01), None
patent: 8-511537 (1996-12-01), None
patent: WO 95/05842 (1995-03-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 99/03483 (1999-01-01), None
U.S. Appl. No. 11/925,942, filed Oct. 27, 2007 Schmidt.
U.S. Appl. No. 11/925,945, filed Oct. 27, 2007 Schmidt.
“AFUD Prostate Cancer Treatment: Treatment”; American Foundation for Urologic Disease; (at least as early as Aug. 5, 2003).
“Continence Management”; The Prostate Cancer Charity; (at least as early as Aug. 8, 2003); 6 pp.
“Inconsistence and the Prostate”; Phoenix5; (at least as early as Aug. 5, 2003); 11 pp.
“Prostate Cancer (PDQ®): Treatment”; National Cancer Institute; (Jul. 17, 2003); 11 pp.
“Prostate Cancer: Prostate Cancer Transrectal Biopsies”; (at least as early as Aug. 20, 2003); 9 pp.
“Prostate Cancer: Tumor Grading”; UPMC Cancer Centers; (2003); 2 pp.
“Prostate Cancer: What are the Treatment Options?”; NSW Health; (Jan. 4, 2002); 2 pp.
“Prostate Gland and Urinary Problems”; Better Health Channel; (Oct. 10, 2001); 10 pp.
“Questions and Answers About the Prostate-Specific Antigen (PSA) Test”; National Cancer Institute; (Jan. 11, 2001); 5 pp.
“Symptoms & Treatments”; Multiple Sclerosis International Federation; pp. 1-6; (as early as 2003).
“The Side Effects of Treatment”; Varian Medical System; (1999-2003); 2 pp.
“Treating Prostate Disease”; The Cleveland Clinic; (Jan. 28, 1999); 3 pp.
“Understanding Gleason Grading”; Phoenix5; (May 14, 1997); 8 pp.
“Western Multiple Sclerosis Center's Glossary; UW Medicine”; (at least before Sep. 30, 2003); 15 pp.
1996 MIMS Annual, Australian Edition. The entry for Botulinum Toxin is located at 5-372.
Amarenco, Lae Revue du Praticien (Paris) 1995 45:343-45.
Amarenco, “Evaluation et Traitment des Dysfoctionnements Vesico-Sphincteriens Neurogenes” Annales d'Urologie 27 (1993) pp. 313-320.
Araki et al. Detrusor-Sphincter Dyssynergia with Special Reference to its Diagnosis and Treatment, J. Saitama Med. School, 1992, 23-27, vol. 19, Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama, Japan (partial translation).
Bardsley; “The Neurogenic Bladder”; Art & Science Continence; (Jan. 7, 2000); pp. 39-41.
Beleggia et al., Arch. It. Urol., LXIX, (S.1): 61-63, 1997 (English Abstract).
Bladderinfo.com: Bladder Control Problems 2004 Pfizer, Inc. www.overactivebladderhelp.com/conditions/problems—bladder.htm, pp. 1-3.
BladderZone.com: Bladder Problems Explained, Pfizer, Ltd., www.bladderzone.com/info/bladder—expl.htm, Copyright 2003, pp. 1-2.
Borodic and Pearce, “New Concepts in Botulinum Toxin Therapy”, Drug Safety 11 (1994), pp. 145 to 152.
Boyd, et al., Lancet 1996 348:481-82.
Bulau, Itherapeutische Perspektiven mit Botulinumtoxin Type A, Neurologie und Rehabilitation, Band 3, Heft 1 (1997) pp. 55-56. (including translation).
Burnstein et al.; “Prostatitis: A Difficult Diagnosis”; DeKalb Clinic Urology; (at least as early as Aug. 20, 2003); 3 pp.
Carl, Stefan, Affidavit, Sep. 26, 2006.
Chancellor et al., J Urol Apr. 2003;169 (Supp 4):351.
Crawford; “Prostate Cancer”; Best Doctors; (Jun. 7, 2000); 6 pp.
DasGupta et al., Urogynaecology 2003, 13:293-299.
Doggweiler et al.: The Prostate, vol. 37, No. 1, pp. 44-50 (1998).
Dykstra et al., Arch. Phys. Med. Rehabil., 71:24-26 (1990).
Dykstra et al.; “Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients”; J. Urology; 139:919-922; (May 1988).
Epstein;“Gleason Score 2-4 Adenocarcinoma of the Prostate on Needle Biopsy”; American Journal of Surgical Pathology; (2000) vol. 24(4); pp. 477-478.
Fowler C J et al: “Myotonic-Like EMG Activity of the Urethral Sphincter in Women With Urinary Retention and the use of Botulinum Toxin to Treat This Disorder” Neurophysiologie Clinique, vol. 20, No. Suppl, 1990, p. 19S, XP009058311 & 5th European Congress of Clinical Neurophysiology, Paris, France, Sep. 9-12, 1990. Neurophysiol.
Fowler et al., British J of Urol., Oct. 22, 1992, vol. 70, 387-389.
Grise, Phillippe, Affidavit, Sep. 26, 2006.
Grosse, Joachim, Affidavit, Sep. 25, 2006.
Han et al., “Botulinum toxin A injection for the treatment of detrusor external sphincter dyssynergia”, (translated abstract), Apr. 2006, pp. 1-3.
Harrison, Principles of Internal Medicine 11th Edition 1987 in particular, pp. 196-197.
Internet presentation on prostate disorders and the anatomy of the prostate/bladder: http://www.farnilydoctor.co.uk/htdocs/PROSTATE/PROSTATE-specimen.htm1 (printed on Dec. 11, 2006).
Internet presentation on prostatitis: http://www.urologyhealth.org/adult/index.cfm?cat=07&topic=I15 (printed on Dec. 11, 2006).
Ishizuka et al., J. Urology, 154:611-616 (1995).
Jankovic J. Related Articles, Links Botulinum toxin in movement disorders. Curr Opin Neurol. Aug. 1994;7(4):358-66.
Jankovic, J, Therapeutic Uses of Botulinum Toxin, NEJM 1991 324(17):1186-94.
Joo et al., Dis. Colon. Rectum, 39:1107-1111 (1996).
Karp Barbara Illowsky et al: “Therapeutic effects of botulinum toxins” 1995, Handbook of Natural Toxins; Bacterial Toxins and Virulence Factors in Disease Marcel Dekker, Inc., New York pp. 1-22.
Khastgir and Shah, Urology News 2001 5:6-8.
Kuo, Hann-Chorng, J Urol Nov. 2003, 170:1908-1912.
Leippold et al., Eur Urol 44 (2003) 165-174.
Maggi et al., J. Urol., 142:150-154 (1989).
Maria et al.; “Relief by Botulinum Toxin of Voiding Dysfunction Due to Prostatitis”; The Lancet; vol. 352, No. 9128, Aug. 1998 p. 625.
Marieb; “Chapter 13: Peripheral Nervous System and Reflex Activity”; Human Anatomy and Physiology, 5th Ed.; (at least as early as Aug. 8, 2003) 5 pp.
Martinez Pinero et al., Pelvic Plexus Denervation in Rats Causes Morphologic and Functional Changes of the Prostate, The Journal of Urology 150 (1993), pp. 215-218.
Medical Pharmacology at a Glance, Blackwell Scientific Publications,1987—pp. 18-19.
MS-Network.com Glossary, Section C; Benecke NI; 2000, pp. 1-4.
Nanninga, John B., Oxins (1993) p. 589-590.
Peak; “Understanding Continence”; The Interdisciplinary Journal of Rehabilitation; (Mar. 2002); 9 pp.
Punch, Gynaecological, and non-gynaecological, chronic pelvic pain, The Lancet, Feb. 21, 1998, 607, vol. 351, Department of OB/BYN, University of Michigan Medical Center, Women's Ho
Condino Debra
Gibson Hal
Kam Chih-Min
The Regents of the University of Colorado
LandOfFree
Use of neurotoxin therapy for treatment of urologic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of neurotoxin therapy for treatment of urologic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of neurotoxin therapy for treatment of urologic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4267801